Skip to main content
Top
Published in: Familial Cancer 1/2008

01-03-2008

Roles and responsibilities of a medical geneticist

Author: Wendy S. Rubinstein

Published in: Familial Cancer | Issue 1/2008

Login to get access

Abstract

Medical geneticists must generate a differential diagnosis, practice evidence-based medicine, and apply ethical, legal, and social issue (ELSI) principles in the clinical setting. Several clinical scenarios are presented which illustrate dilemmas in the cancer genetics setting. These include the differential diagnosis of breast and gastric cancer, and the predicament posed by the need to practice evidence-based medicine in light of limitations in the medical genetics literature, which may mean recommending prophylactic surgery. Also discussed are three BRCA1/2 genetic testing scenarios which illustrate the difficulty of knowing where to “draw the line”, i.e., when to offer testing and what level of testing to pursue. Decision-making about BRCA1/2 gene testing including Ashkenazi Jewish founder mutation testing, comprehensive reflex testing, and expedited testing, is explored. The duty to recontact as standard of care evolves requires that medical geneticists determine how to prospectively set expectations with patients as well as to decide which situations require recontact and to determine how to systematically do so. The case of patient recontact regarding new mutation detection techniques with improved sensitivity, e.g., BART testing which is based on the ability to detect large BRCA1/2 rearrangements, is discussed. General principles are highlighted so that these specific cases can be extrapolated to other genes and hereditary conditions by medical geneticists, genetic counselors, and others practicing in the field of cancer genetics.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90(3):114–133PubMedCrossRef Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90(3):114–133PubMedCrossRef
3.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef
4.
go back to reference Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed
5.
go back to reference Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed
6.
go back to reference Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35(8):1248–1257PubMedCrossRef Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35(8):1248–1257PubMedCrossRef
7.
go back to reference Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. Bmj 312(7023):71–72PubMed Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. Bmj 312(7023):71–72PubMed
8.
go back to reference Liede A, Metcalfe K, Offit K et al (1998) A family with three germline mutations in BRCA1 and BRCA2. Clin Genet 54(3):215–218PubMedCrossRef Liede A, Metcalfe K, Offit K et al (1998) A family with three germline mutations in BRCA1 and BRCA2. Clin Genet 54(3):215–218PubMedCrossRef
9.
go back to reference Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef
10.
go back to reference Kauff ND, Perez-Segura P, Robson ME et al (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39(8):611–614PubMedCrossRef Kauff ND, Perez-Segura P, Robson ME et al (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39(8):611–614PubMedCrossRef
11.
go back to reference Rubinstein WS, O’Neill SM, Peters JA, Rittmeyer LJ, Stadler MP (2002) Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Huntingt) 16(8):1082–1094 Rubinstein WS, O’Neill SM, Peters JA, Rittmeyer LJ, Stadler MP (2002) Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Huntingt) 16(8):1082–1094
12.
go back to reference Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823–1829PubMedCrossRef Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823–1829PubMedCrossRef
13.
go back to reference Fitzpatrick JL, Hahn C, Costa T, Huggins MJ (1999) The duty to recontact: attitudes of genetics service providers. Am J Hum Genet 64(3):852–860PubMedCrossRef Fitzpatrick JL, Hahn C, Costa T, Huggins MJ (1999) The duty to recontact: attitudes of genetics service providers. Am J Hum Genet 64(3):852–860PubMedCrossRef
14.
go back to reference Rubinstein WS, Roy HK (2005) Practicing medicine at the front lines of the genomic revolution. Arch Intern Med 165(16):1815–1817PubMedCrossRef Rubinstein WS, Roy HK (2005) Practicing medicine at the front lines of the genomic revolution. Arch Intern Med 165(16):1815–1817PubMedCrossRef
15.
go back to reference Locker GY, Kaul K, Weinberg DS et al (2006) The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 169(1):33–38PubMedCrossRef Locker GY, Kaul K, Weinberg DS et al (2006) The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 169(1):33–38PubMedCrossRef
16.
go back to reference Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388PubMedCrossRef Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388PubMedCrossRef
Metadata
Title
Roles and responsibilities of a medical geneticist
Author
Wendy S. Rubinstein
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2008
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9148-6

Other articles of this Issue 1/2008

Familial Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine